Society of Nuclear Medicine, Journal of Nuclear Medicine, 7(51), p. 1123-1130, 2010
DOI: 10.2967/jnumed.110.076521
Full text: Download
The development of novel multimodality imaging agents and techniques represents the current frontier of research in the field of medical imaging science. However, the combination of nuclear tomography with optical techniques has yet to be established. Here, we report the use of the inherent optical emissions from the decay of radiopharmaceuticals for Cerenkov luminescence imaging (CLI) of tumors in vivo and correlate the results with those obtained from concordant immuno-PET studies.